La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

cbdMD Dividendo

Dividendo criteri di controllo 0/6

cbdMD non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.1%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$6.22
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

Mar 23

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Feb 23

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Feb 09

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

Jan 13

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

Dec 15

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di YCBD siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di YCBD siano aumentati.

Rendimento dei dividendi rispetto al mercato

cbdMD Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di YCBD rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (YCBD)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Pharmaceuticals)	2.1%
Previsione dell'analista in 3 anni (YCBD)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di YCBD rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di YCBD rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di YCBD per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché YCBD non ha segnalato alcun pagamento.

cbdMD Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Consensus EPS estimates upgraded to US$2.63 loss

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

cbdMD Receives Non-Compliance Letter from NYSE American Regarding Shareholders Equity

Consensus revenue estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc., Annual General Meeting, Mar 29, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Share price stability

Third quarter 2023 earnings released: US$1.16 loss per share (vs US$24.76 loss in 3Q 2022)

Second quarter 2023 earnings released: US$1.74 loss per share (vs US$4.32 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.082 loss per share (vs US$0.35 loss in 1Q 2022)

cbdMD Appoints Shannon Charles as Chief Marketing Officer

cbdMD, Inc., Annual General Meeting, Feb 16, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$0.47 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

cbdMD, Inc. Announces Board Changes

Insufficient new directors

cbdMD, Inc. Announces Resignation of Scott Coffman as Co-Chief Executive Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

cbdMD Requests the Food and Drug Administration (FDA) Remove the Drug Exclusion for CBD and Review cbdMD’s Extensive Safety Submission

cbdMD Becomes First American CBD Brand to Receive Validation by the United Kingdom Food Standards Agency

cbdMD, Inc. Becomes the First CBD Company to Earn NSF International’s Certified for Sport Certification

cbdMD, Inc., Annual General Meeting, Mar 11, 2022

cbdMD, Inc. Withdraws Revenue Guidance for the Quarter Ending December 31, 2021

cbdMD, Inc. Launches New Full Spectrum Product Line

cbdMD, Inc. Revises Sales Guidance for the First Quarter of Fiscal 2022

Third quarter 2021 earnings released: EPS US$0.017 (vs US$0.18 loss in 3Q 2020)

Consensus EPS estimates fall to -US$0.45

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.41 profit in 2Q 2020)

cbdMD, Inc. Provides Net Sales Guidance for the First Quarter of Fiscal 2022

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

cbdMD, Inc. Elects Sim Farar as Director

Chairman & Co-CEO recently sold US$240k worth of stock

cbdMD, Inc. Announces Order by Court Staying California Litigation

Independent Director recently sold US$81k worth of stock

cbdMD, Inc. Appoints T. Ronan Kennedy to Serve as Chief Operating Officer

Independent Director notifies of intention to sell stock

Chairman & Co-CEO recently sold US$1.8m worth of stock

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Chairman & Co-CEO notifies of intention to sell stock

Price target raised to US$6.03

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.47 profit in 1Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Investor sentiment improved over the past week

New 90-day high: US$4.14

Price target raised to US$5.77

cbdMD, Inc., Annual General Meeting, Mar 12, 2021

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

New 90-day high: US$3.40

Investor sentiment improved over the past week

cbdMD Enters Global Beauty and Skincare Market With Launch of “cbdMD Botanicals”

Price target raised to US$5.53

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: EPS US$0.28

New 90-day high: US$3.36

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

New 90-day high: US$3.01

Market bids up stock over the past week

New 90-day low: US$1.84

Pro Group, Inc. Selects cbdMD and Paw CBD as Exclusive Distributor of CBD Brands

cbdMD, Inc Announces Resignation of Mark Elliott as Chief Operating Officer, effective October 01, 2020

Price target raised to US$4.87

Analysts increase EPS estimates to US$0.72

cbdMD, Inc.(AMEX:YCBD) dropped from Russell Small Cap Completeness Index

cbdMD, Inc.(AMEX:YCBD) dropped from Russell Microcap Value Index

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti